Crucell sales and marketing update

Crucell announced that it has placed a temporary hold on shipments and manufacturing of marketed vaccines Quinvaxem and Hepavax-gene at its Shingal, South Korea, facility. The hold is due to the possibility that the sterile facility, which was already scheduled to be vacated next year, was compromised during recent operations. The company expects to resume shipping before the end of the month with full availability of both vaccines expected by February 2011. Crucell said it will update its latest financial guidance as soon as possible. ...